KALA BIO, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by KALA BIO, Inc. on February 12, 2025, reporting events that occurred on February 11, 2025. The Company is a biopharmaceutical entity incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol "KALA".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is a significant leadership transition within the executive suite:
- Resignation of CEO: Mark Iwicki resigned as Chief Executive Officer effective immediately on February 11, 2025. He will continue to serve as the Chair of the Board of Directors.
- Appointment of Interim CEO: The Board appointed Todd Bazemore as Interim Chief Executive Officer and principal executive officer, effective immediately on February 11, 2025.
Management Commentary and Background
Todd Bazemore, 54, brings extensive experience to the interim role. He has served as the Company's President since December 2021 and Chief Operating Officer since November 2017. His prior experience includes roles at Santhera Pharmaceuticals, Dyax Corp., and Sunovion Pharmaceuticals, with a focus on commercial operations, sales, and market access. The filing confirms no family relationships between Mr. Bazemore and other officers or directors and no undisclosed transactional interests.
Investor Verification Checklist
- Verify the effective date of the CEO transition (February 11, 2025).
- Confirm the continued role of Mark Iwicki as Chair of the Board.
- Review the Company's subsequent press releases or 10-Q/10-K filings for any financial impact related to this leadership change.
- Check for any pending compensation arrangements or severance agreements for the departing CEO not detailed in this 8-K.